PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study - Pegram, MD; Bondarenko, I; Zorzetto, MMC (Br J Cancer, 2019)
et al.